当前位置: 首页 >> 检索结果
201. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Statin product labels (eg, Summaries of Product Characteristics [SmPCs]) list certain adverse outcomes as potential treatment-related effects based mainly on non-randomised and non-blinded studies, which might be subject to bias. We aimed to assess the evidence for such undesirable effects more reliably through a meta-analysis of individual participant data from large double-blind trials of statin therapy.
204. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Mazen Noureddin.;Kris V Kowdley.;Tatjana Odrljin.;Gerard Bain.;Jeff Zhao.;Brenda Jeglinski.;Margaret James Koziel.;Rohit Loomba.
来源: Lancet. 2026年407卷10530期794-804页
The growing prevalence of metabolic dysfunction-associated steatohepatitis (MASH) underscores the unmet need for effective and safe liver-targeted therapies to prevent fibrosis and disease progression. The aim of this study was to evaluate the efficacy and safety of efimosfermin alfa (henceforth referred to as efimosfermin, formerly BOS-580), an FGF21 analogue taken once per month, in patients with MASH and moderate or advanced fibrosis.
207. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.
作者: Amy E Colson.;Anthony M Mills.;Moti N Ramgopal.;Christopher Bettacchi.;Olayemi O Osiyemi.;Federico Hinestrosa.;Gordon Crofoot.;Harold P Katner.;Hiroyuki Gatanaga.;Margaret Johnson.;Tracy L Diamond.;Erika Barninger.;Karen Eves.;Feng-Hsiu Su.;Yayun Xu.;Stephanie O Klopfer.;Luisa M Stamm.;Michelle C Fox.;Rima Lahoulou.
来源: Lancet. 2026年407卷10528期611-621页
The combination of doravirine and islatravir is under investigation as a fixed-dose, single-tablet regimen for the treatment of HIV-1. We aimed to assess the efficacy and safety of switching to doravirine (100 mg) and islatravir (0·25 mg) from bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV-1.
208. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.
作者: Chloe Orkin.;Rosie Mngqibisa.;Juan Diego Velez.;Princy Kumar.;Dominique L Braun.;Andrew Carr.;Mark Bloch.;Sharon Walmsley.;Pablo Tebas.;Yoshiyuki Yokomaku.;Tracy L Diamond.;Beth Jackson.;Karen Eves.;Anjana Grandhi.;Monica Fuszard.;Stephanie O Klopfer.;Luisa M Stamm.;Michelle C Fox.;Jason Kim.
来源: Lancet. 2026年407卷10528期599-610页
Doravirine and islatravir is an investigational, once-daily, single-tablet regimen containing two potent antiretrovirals with complementary mechanisms of action and resistance profiles. We aimed to evaluate the efficacy and safety of switching from stable, oral antiretroviral therapy (ART) to the fixed combination of doravirine (100 mg) and islatravir (0·25 mg) in virologically suppressed adults living with HIV-1.
216. Improvisation in contexts of infrastructural violence: a physician practising medicine in Sahrawi refugee camps.
作者: Salek Ali Mohamed Elabd.;Laroussi Mohamed Salem.;Theodore L Michaels.;Dahaman Bachir Hamadi.;Raabub Mohamed-Lamin Mehdi.;María Carrión.;Seth M Holmes.
来源: Lancet. 2026年407卷10528期566-567页 |